Qiagen Stock Price, News & Analysis

QIAGEN has partnered with Servier to develop a PCR test for detecting isocitrate dehydrogenase-1 (IDH1) mutations in acute myeloid leukemia (AML) patients. This companion diagnostic will be utilized with Servier’s TIBSOVO®, an IDH1 inhibitor treatment. The test will run on QIAGEN's Rotor-Gene Q device, targeting blood and bone marrow samples. QIAGEN, a leader in companion diagnostics, collaborates with over 30 companies to advance precision medicine. The collaboration aims to enhance patient access to targeted treatments for the 6-10% of AML patients with IDH1 mutations, showcasing QIAGEN's commitment to innovation in oncology diagnostics.

SOPHiA GENETICS (Nasdaq: SOPH) has entered into a partnership with QIAGEN (NYSE: QGEN) to integrate QIAseq reagent technology with its SOPHiA DDM™ platform. This collaboration aims to enhance tumor analysis through next-generation sequencing (NGS), specifically supporting somatic variant detection related to homologous recombination repair. The partnership allows customers to access QIAseq panels for improved data analysis, enhancing research capabilities in oncology. Both companies are optimistic about the positive impact on medicine and research.

QIAGEN N.V. (NYSE: QGEN) has launched the QIAseq Platform Partnership with SOPHiA GENETICS (NASDAQ: SOPH), aimed at improving the compatibility of QIAGEN's NGS kits with digital data-sharing platforms. This collaboration will enable somatic variant detection using QIAseq panels for homologous recombination repair, enhancing research in precision diagnostics. The partnership is set to expand to custom solutions, allowing greater access to data-driven medicine. Notably, QIAGEN has processed about four million samples with their NGS panels, solidifying their position in the genomics market.

QIAGEN has announced the certification of its QuantiFERON-TB Gold Plus test under the new EU In Vitro Diagnostic Medical Devices Regulation (IVDR), classified as Class C. This certification marks a key milestone in QIAGEN's compliance with EU regulations aimed at enhancing diagnostic performance and safety. The QuantiFERON-TB Gold Plus test is recognized globally, including by WHO, for its effectiveness in detecting tuberculosis. As part of its commitment, QIAGEN is transitioning over 180 products to meet the IVDR standards, ensuring continued supply and compliance moving forward.

QIAGEN N.V. (NYSE: QGEN) reported Q4 2022 net sales of $498 million, a 14% decline year-over-year, with sales at constant exchange rates (CER) at $531 million. The adjusted diluted EPS was $0.53, exceeding expectations. Non-COVID product sales grew 15% to $432 million. For full-year 2022, net sales were $2.14 billion with a 5% decline but profits were strong, showing adjusted diluted EPS of $2.38. Looking ahead, QIAGEN aims for 2023 net sales of at least $2.05 billion with continued growth in non-COVID products.

QIAGEN has launched the EZ2 Connect MDx platform for diagnostic laboratories, enhancing sample processing capabilities 18 months after its research introduction. This automated device purifies DNA and RNA from 24 samples in approximately 30 minutes and is CE-IVD compliant, enabling its use across the EU, U.S., Canada, and more. With over 5,000 EZ platforms deployed globally, EZ2 Connect MDx integrates with the QIAsphere digital system for remote management, meeting the fast-paced demands of clinical diagnostics. It addresses various sample types, employing magnetic-bead technology and ensuring high process safety.

QIAGEN N.V. (NYSE: QGEN) has announced its upcoming fourth quarter and full-year 2022 results, set to be released on February 7 at 22:05 Frankfurt time. Following this, a conference call is scheduled for February 8 at 15:00 Frankfurt time, where key business updates and financial performance will be discussed. The company provides solutions in molecular diagnostics, applied testing, pharma, and academia, serving over 500,000 customers globally. As of September 30, 2022, QIAGEN employed over 6,200 people across 35 locations worldwide.

QIAGEN has announced the completion of its acquisition of Verogen for $150 million in cash, enhancing its position in the next-generation sequencing (NGS) market for forensic applications. This acquisition follows a partnership that began in June 2021 and is expected to generate $20 million in sales from Verogen’s offerings in 2023. However, it will be dilutive to QIAGEN’s adjusted EPS by about $0.03 per share for 2023. The integration of Verogen’s technology is anticipated to broaden QIAGEN’s capabilities in human identification and forensic investigations.

QIAGEN has entered an exclusive partnership with Helix to enhance companion diagnostics for hereditary diseases. The collaboration will utilize Helix's laboratory platform and QIAGEN's regulatory expertise to accelerate patient recruitment and real-world evidence generation. This partnership aims to provide innovative diagnostic solutions for neuro-degenerative, cardiovascular, and autoimmune diseases, benefiting hundreds of millions globally. QIAGEN will exclusively market Helix's companion diagnostic services in the U.S., leveraging their extensive network and experience in precision medicine.